|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1992-2-21
|
|
pubmed:abstractText |
Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been established.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
13
|
|
pubmed:volume |
326
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
437-43
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:1346337-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:1346337-Adult,
pubmed-meshheading:1346337-CD4-Positive T-Lymphocytes,
pubmed-meshheading:1346337-Double-Blind Method,
pubmed-meshheading:1346337-Female,
pubmed-meshheading:1346337-Follow-Up Studies,
pubmed-meshheading:1346337-HIV Infections,
pubmed-meshheading:1346337-Humans,
pubmed-meshheading:1346337-Leukocyte Count,
pubmed-meshheading:1346337-Male,
pubmed-meshheading:1346337-Patient Compliance,
pubmed-meshheading:1346337-Survival Rate,
pubmed-meshheading:1346337-Time Factors,
pubmed-meshheading:1346337-Zidovudine
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
|
|
pubmed:affiliation |
Department of Veterans Affairs Medical Centers, Baltimore.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Multicenter Study
|
